Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (8,805)	$ (8,022)
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	2,976	2,712
Depreciation and amortization	4,163	2,373
Current and deferred income taxes	(4,516)	6,944
Non-cash development expenses from joint venture	190	1,212
Impairment of in-process research and development	0	9,600
Change in fair value of contingent value rights	0	(3,005)
Excess tax benefits from stock-based compensation	(1,608)	(1,118)
Other	6	(19)
Changes in operating assets and liabilities:
Accounts receivable	33,079	30,501
Inventories	(6,987)	(2,658)
Income taxes	(7,918)	(11,154)
Prepaid expenses and other assets	(246)	443
Accounts payable	(4,196)	(1,988)
Accrued expenses and other liabilities	21	(11)
Accrued compensation	(10,982)	(10,895)
Deferred revenue	197	(1,075)
Net cash provided by (used in) operating activities	(4,626)	13,840
Cash flows from investing activities:
Purchases of property, plant and equipment	(7,679)	(22,329)
Proceeds from sale of assets	0	11,765
Proceeds from maturity of investments	0	1,966
Net cash used in investing activities	(7,679)	(8,598)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	0	9,621
Issuance of common stock subject to exercise of stock options	504	242
Excess tax benefits from stock-based compensation	1,608	1,118
Principal payments on long-term indebtedness	(1,117)	(8,203)
Contingent value right payment	0	(1,748)
Restricted cash	0	220
Net cash provided by financing activities	995	1,250
Effect of exchange rate changes on cash and cash equivalents	(118)	32
Net increase (decrease) in cash and cash equivalents	(11,428)	6,524
Cash and cash equivalents at beginning of period	141,666	143,901
Cash and cash equivalents at end of period	$ 130,238	$ 150,425